Samuel Denmeade
Johns Hopkins University · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Samuel Denmeade as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:11 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07142551 · Supraphysiologic Testosterone Priming Induces Darolutamide Extended ResponseSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · recruiting · Metastatic Castration-resistant Prostate Cancer · principal investigator
- Ph2NCT06922318 · The COSMYC Trial (COmbined Suppression of MYC)Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · recruiting · Metastatic Castration-resistant Prostate Cancer · principal investigator
- Ph2NCT05081193 · Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · active not recruiting · Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer · principal investigator
- Ph2NCT04704505 · Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · recruiting · Prostate Adenocarcinoma, Metastatic Prostate Adenocarcinoma, Castration-resistant · principal investigator
- Ph2NCT04363164 · Sequential Testosterone and Enzalutamide Prevents Unfavorable ProgressionSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · recruiting · Castration Resistant Metastatic Prostate Cancer · principal investigator
- Ph1NCT02995330 · Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · terminated · Prostate Cancer · principal investigator
- N/ANCT02491411 · Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and DocetaxelSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · terminated · Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma · principal investigator
- Ph2NCT02286921 · Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide ResistanceSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Castration Resistant Metastatic Prostate Cancer · principal investigator
- Ph2NCT02090114 · RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Prostate Cancer · principal investigator
- Ph1NCT01983709 · Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · terminated · Prostate Cancer · principal investigator
- Ph2NCT01750398 · Bipolar Androgen-based Therapy for Prostate Cancer (BAT)Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Recurrent Prostate Cancer · principal investigator
- N/ANCT01084759 · A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:11 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Androgen Activation of Innate Immune Signaling to Enhance Prostate Cancer Immune ResponseR01CA243184 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2022 to 2026 · $495,606 awarded in 2026Same name and institution; not confirmed by an ID
- Project 1: Combined Suppression of MYC as therapy for CRPC: the COSMYC trialP50CA272391 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2024 to 2026 · $381,804 awarded in 2026Grant number is on one of their registry trials
- The Role of Myeloid-Derived Suppressor Cells in Resistance to Bipolar Androgen Therapy in Patients with Advanced Prostate CancerR21CA273501 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2023 to 2024 · $181,813 awarded in 2024Same name and institution; not confirmed by an ID
- SPORE in Prostate CancerP50CA058236 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2017 to 2020 · $1,478,967 awarded in 2020Same name and institution; not confirmed by an ID
- Bipolar Androgen Therapy for Progressive Castrate Resistant Prostate CancerR01CA184012 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2014 to 2018 · $261,450 awarded in 2018Grant number is on one of their registry trials
- Fibroblast Activation Protein-alpha Activated Anti-Stromal Prodrug Therpay for CaR01CA124764 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2007 to 2010 · $311,600 awarded in 2010Same name and institution; not confirmed by an ID
- Synthesis and MAPK Kinase Inhibitiory Activities in Prostate TumorsU54CA091409 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2006 to 2010 · $145,442 awarded in 2010Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Chemical and Structural BiologyP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI James M. Berger · fiscal years 2013 to 2026Named on NCT02491411
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:11 UTC. The ranking covers the 200 most relevant of 43 PubMed records, and a shared surname and initials can bring in a namesake. All 43 on PubMed
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.JAMA Oncol · 2020988 citationsRCR 46.6
- Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.J Clin Oncol · 2010342 citationsRCR 8.9
- Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.Sci Transl Med · 2015221 citationsRCR 6.3
- Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.Sci Transl Med · 2012183 citationsRCR 4.9
- Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.Lancet Oncol · 2018156 citationsRCR 4.8
- 127 citationsRCR 4.5
- TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.J Clin Oncol · 2021122 citationsRCR 6.0
- 111 citationsRCR 8.2
- 103 citationsRCR 4.1
- A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).BMC Cancer · 201790 citationsRCR 2.9